Actinium-225 HER3 targeted radiotherapy - Actinium Pharmaceuticals/AVEO Oncology
Alternative Names: Ac-225 ErbB3 targeted radiotherapy-Actinium Pharmaceuticals/AVEO Oncology; Ac-225 HER3 targeted radiotherapy - Actinium Pharmaceuticals/AVEO Oncology; Ac-225-HER3 antibody radio conjugate; Ac-225-HER3-ARC - Actinium Pharmaceuticals; Actinium-225 ErbB3 targeted radiotherapy; Anti-HER3 antibody radioconjugateLatest Information Update: 16 Jun 2023
At a glance
- Originator Actinium Pharmaceuticals; AVEO Oncology
- Class Antineoplastics; Drug conjugates; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from the preclinical studies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 11 Apr 2022 Preclinical trials in Solid tumours in USA (unspecified route)
- 11 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumours released by Actinium Pharmaceuticals